Beat Flühmann

Equivalence of complex drug products: advances in and challenges for current regulatory frameworks

L. Hussaarts, Stefan Mühlebach, Vinod P. Shah et al. · Annals of the New York Academy of Sciences · 2017 · 82 citations · Full text

Preclinical Therapeutics, World Health Organization, Engineering +18

The similarity question for biologicals and non-biological complex drugs

Daan J.A. Crommelin, Vinod P. Shah, Imre Klebovich et al. · European Journal of Pharmaceutical Sciences · 2015 · 68 citations · Full text

Engineering, Drug Class, Drug Resistance +17

Nanoparticle iron medicinal products – Requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies

Gerrit Borchard, Beat Flühmann, Stefan Mühlebach · Regulatory Toxicology and Pharmacology · 2012 · 64 citations

Nanoparticles, Nanomedicine, Pharmaceutical Research +13

How to select a nanosimilar

A. Astier, Amy Barton Pai, Marco Bissig et al. · Annals of the New York Academy of Sciences · 2017 · 42 citations · Full text

The Growing Field of Nanomedicine and Its Relevance to Pharmacy Curricula

Volkmar Weissig, Tamer Elbayoumi, Beat Flühmann et al. · American Journal of Pharmaceutical Education · 2021 · 26 citations · Full text

Nanoparticles, Nanotherapeutics, Engineering +17